Strs Ohio cut its position in C.R. Bard, Inc. (NYSE:BCR) by 28.8% during the second quarter, Holdings Channel reports. The fund owned 4,899 shares of the medical instruments supplier’s stock after selling 1,979 shares during the period. Strs Ohio’s holdings in C.R. Bard were worth $1,548,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. BlackRock Inc. raised its stake in shares of C.R. Bard by 1,365.7% in the first quarter. BlackRock Inc. now owns 7,398,081 shares of the medical instruments supplier’s stock worth $1,838,719,000 after buying an additional 6,893,346 shares during the last quarter. MARSHALL WACE ASIA Ltd acquired a new stake in shares of C.R. Bard during the first quarter worth approximately $132,062,000. Marshall Wace North America L.P. acquired a new stake in shares of C.R. Bard during the first quarter worth approximately $132,062,000. Renaissance Technologies LLC raised its stake in shares of C.R. Bard by 87.8% in the first quarter. Renaissance Technologies LLC now owns 956,700 shares of the medical instruments supplier’s stock worth $237,778,000 after buying an additional 447,300 shares during the last quarter. Finally, Alliancebernstein L.P. raised its stake in shares of C.R. Bard by 267.0% in the first quarter. Alliancebernstein L.P. now owns 491,184 shares of the medical instruments supplier’s stock worth $122,079,000 after buying an additional 357,355 shares during the last quarter. 85.32% of the stock is owned by institutional investors.

C.R. Bard, Inc. (NYSE:BCR) opened at 319.75 on Friday. C.R. Bard, Inc. has a 12-month low of $203.63 and a 12-month high of $323.27. The firm has a 50-day moving average price of $319.00 and a 200-day moving average price of $283.44. The company has a market cap of $23.24 billion, a P/E ratio of 41.98 and a beta of 0.59.

C.R. Bard (NYSE:BCR) last issued its earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.84 by $0.08. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The business had revenue of $979.70 million during the quarter, compared to analysts’ expectations of $976.53 million. During the same period in the prior year, the business earned $2.54 EPS. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. On average, equities research analysts forecast that C.R. Bard, Inc. will post $11.84 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, August 4th. Shareholders of record on Monday, July 24th were issued a $0.26 dividend. This represents a $1.04 annualized dividend and a dividend yield of 0.33%. The ex-dividend date was Thursday, July 20th. C.R. Bard’s dividend payout ratio is 13.67%.

COPYRIGHT VIOLATION NOTICE: “C.R. Bard, Inc. (NYSE:BCR) Shares Sold by Strs Ohio” was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/c-r-bard-inc-nysebcr-shares-sold-by-strs-ohio/1476534.html.

BCR has been the subject of a number of research analyst reports. Zacks Investment Research raised C.R. Bard from a “hold” rating to a “buy” rating and set a $342.00 price target for the company in a research note on Thursday, May 11th. BidaskClub raised C.R. Bard from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 8th. Morgan Stanley lowered C.R. Bard from an “overweight” rating to an “equal weight” rating in a research note on Monday, April 24th. Jefferies Group LLC raised their price target on C.R. Bard from $237.00 to $317.00 and gave the stock a “hold” rating in a research note on Monday, April 24th. Finally, Raymond James Financial, Inc. lowered C.R. Bard from a “strong-buy” rating to a “mkt perform” rating in a research note on Wednesday, April 26th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $285.67.

In other C.R. Bard news, insider John P. Groetelaars sold 23,687 shares of the company’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $318.73, for a total value of $7,549,757.51. Following the completion of the sale, the insider now directly owns 31,445 shares in the company, valued at approximately $10,022,464.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.80% of the stock is currently owned by corporate insiders.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.